Analgesic effect of nefopam on enhanced recovery after minimally invasive spine surgery: a randomized prospective study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20190525001

Enrollment

100

Registered

2019-05-25

Start date

2019-07-22

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing minimally invasive spine surgery nefopam&#44

Interventions

Nefopam 20 mg IV at the end of operation and continuous infusion 80 mg in first 24 hours postoperatively,Normal saline iv infusion

Active Comparator Drug,Placebo Comparator No treatment

Nefopam group,Normal saline group

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients undergoing minimally invasive spine surgery (MIS) ASA physical status I-III

Exclusion criteria

Exclusion criteria: - Allergy to medications used in protocol - History of seizure, MI, glaucoma - Concurrent use MAO inhibitors - Liver cirrhosis or end-stage renal disease (ESRD)

Design outcomes

Primary

Measure	Time frame
Morphine consumption 24 hours mg	—

Secondary

Measure	Time frame
Time to first ambulation since operation complete hours,Hospital stay since operation complete days,Duration of tubing (drain and Foley) removal since operation complete hours,Postoperative pain score until day 3 Numerical rating scale 0-10,Incidence of neuropathic pain 24 hours Neuropathic pain questionnaire	—

Countries

Thailand

Contacts

Public ContactPornpan Chalermkitpanit

Department of Anesthesiology, Chulalongkorn University

pornpan.c@chula.ac.th0894554847

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026